Table 4.
Intergroup comparison between changes from baseline at the end of the Study
| Parameters | Placebo (n=29) | NXT15906F6- 250 (n=30) | NXT15906F6- 400 (n=30) | *p value between mean changes | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Placebo vs. NXT15906F6- 250 | Placebo vs. NXT15906F6- 400 | |
| Stair climbing time (s) | 0.30±1.01 | -2.27 ±1.46 | -2.40 ±1.28 | <0.0001 | <0.0001 |
| Visual analogue scale (VAS) Score | -1.38±1.85 | -4.19±2.44 | -6.21±2.06 | <0.0001 | <0.0001 |
| WOMAC-A (pain) score | -6.21±9.42 | -16.33±15.14 | -23.83±8.97 | <0.0001 | <0.0001 |
| WOMAC-B (Stiffness) score | 0.86±5.36 | -6.17±8.97 | -9.17±7.78 | <0.0001 | <0.0001 |
| WOMAC-C (Physical function) scores | -12.93±18.20 | -39.00±29.81 | -70.17±31.25 | <0.0001 | <0.0001 |
| Total WOMAC score | -18.28±28.98 | -61.50±49.10 | -103.17±39.49 | <0.0001 | <0.0001 |
| Primary knee flexion (degrees) | 1.03±1.45 | 3.43±1.61 | 5.30±1.29 | <0.0001 | <0.0001 |
Data presented as mean±SD, *p-value, the comparison between the mean change of baseline scores placebo and mean changes from baseline scores in NXT15906F6 groups at day 90 are analyzed using an ANCOVA model.